BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) has added two potential cancer therapies to its pipeline - BVX002 and BVX003. They join BVX001, a putative.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) s Chief executive Tiffany Thorn talks to Proactive London about their method and adding two potential cancer.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) is looking to strengthen its intellectual property base with four UK patent applications related to several.